Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|May 25, 2017
Metastatic Lung Adenocarcinoma Without a Driver Mutation
Metastatic Lung Adenocarcinoma Without a Driver Mutation
Advertisement
- A 70-year-old Caucasian female presented with mild dyspnea and no chest pain.
- She has also experienced recent, rapid weight loss (>10 pounds in 1.5 months) without any changes in her diet or exercise pattern.
- She gave up smoking 7 years ago (2 packs per day for 35 years).
- Her medical history is unremarkable:
- A few years ago, she was diagnosed with gastroesophageal reflux disease that was clinically and endoscopically confirmed.
- She has no history of cancer in the family.
- Her cardiac workup is negative.
- Her PS by ECOG assessment was 0.
- Chest x-ray showed a 2.5-cm lesion in her right lower lobe.
- CT scan of the chest and abdomen confirmed the presence of the lung mass in addition to numerous bilateral nodules, all about 5 to 9 mm, in the right upper and lower lobes and the left upper and lower lobes, as well as enlargement of hilar lymph nodes. In addition, 3 small nodules were seen in the liver, measuring 1 to 2 mm.
- PET/CT imaging showed 18F-FDG uptake in the lung mass, left hilar lymph nodes, and liver.
- MRI of the brain was negative for intracranial metastases.
- A core biopsy of the lung nodule was performed:
- Its morphology and molecular phenotype (TTF-1-positivity) supported a diagnosis of lung adenocarcinoma.
- Mutational testing showed absence of driver mutations (i.e., was negative forEGFR, ROS, andALK).
- PD-L1 testing showed PD-L1 expression of 35%.
- The patient was diagnosed with stage IV metastatic NSCLC.
- The patient was started on therapy with a chemotherapy doublet and bevacizumab (Avastin).
- At her next follow-up 2 months later, her CT scan showed the right lung mass to be stable, with no new lesions. She has improved symptomatically.
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5